<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04354467</url>
  </required_header>
  <id_info>
    <org_study_id>300000362</org_study_id>
    <nct_id>NCT04354467</nct_id>
  </id_info>
  <brief_title>Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU</brief_title>
  <official_title>Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) Ito Predict Acute Kidney Injury (AKI) in the NICU in Infants Receiving Multiple Nephrotoxic Medications (NICU NINJA NGAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute
      kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of
      cases. Through initial work at UAB/Children's of Alabama Hospital, NTMx exposure was found to
      be potentially modifiable and the associated AKI is an avoidable adverse safety event.
      Currently, only serum Creatinine monitoring is available to monitor for NTMx-associated AKI.
      The hypothesis of this NINJA NGAL study is that urine NGAL is highly sensitive to detect
      NTMx-associated AKI. UAB/Children's of Alabama is bringing urine NGAL measurement to the
      infants in the NICU to detect NTMX-associated AKI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nephrotoxic medication-induced acute kidney injury (NTM-AKI) is a relevant yet underdiagnosed
      morbidity in the neonatal intensive care unit (NICU).

      Up to 87% of very low birth weight infants are exposed to at least one nephrotoxic medication
      (NTM). NTM-AKI is associated with poor short and long-term outcomes.

      Presently, no treatments exist for AKI beyond supportive care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with elevated urine NGAL</measure>
    <time_frame>Daily for one week after meeting criteria for nephrotoxic medication exposure</time_frame>
    <description>NGAL is an early, sensitive, non-invasive urine biomarker for AKI.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Nephrotoxicity</condition>
  <condition>Neonatal</condition>
  <arm_group>
    <arm_group_label>Acute Kidney Injury due to Nephrotoxic medication</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>No Acute Kidney Injury due to Nephrotoxic Medications</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acute kidney Injury due to nephrotoxic medications in the NICU</intervention_name>
    <description>AKI will be defined using the KDIGO AKI definition</description>
    <arm_group_label>Acute Kidney Injury due to Nephrotoxic medication</arm_group_label>
    <arm_group_label>No Acute Kidney Injury due to Nephrotoxic Medications</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Neonatal Intensive Care Unit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all NICU inpatients under 1 year of age; greater than 4 days of age that are

               -  Receiving 3 or more nephrotoxic medications on the same day OR

               -  Receiving 3 or more days of an intravenous aminoglycoside or vancomycin

        Exclusion Criteria:

          -  Less than 4 days of age

               -  Currently being treated for a urinary tract infection

               -  Presence of an acute kidney injury prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Askenazi</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Dill, BSN</last_name>
    <phone>205-638-9347</phone>
    <email>ldill@peds.uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Askenazi, MD</last_name>
    <phone>205-638-9781</phone>
    <email>daskenazi@peds.uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Dill, BSN</last_name>
      <phone>205-638-9347</phone>
      <email>ldill@peds.uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelli Krallman, BSN</last_name>
      <phone>512-636-4837</phone>
      <email>Kelli.Krallman@cchmc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>David Askenazi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>to be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

